
Launching A New Era in Bispecific Antibody Drug Development
WuXiBody® is an innovative, proprietary technology platform developed by WuXi Biologics for the expanding field of bispecific antibodies. Based on novel engineering, the platform can expedite the drug development process by 6-18 months and significantly reduce production costs. The WuXiBody platform enables almost any monoclonal antibody (mAb) sequence pair to be assembled into the bispecific construct and its unique structural flexibility makes the platform convenient to build various formats with different valency (e.g., 2, 3 or 4 binding sites).